SVB Leerink Maintains Outperform on Nurix Therapeutics, Raises Price Target to $64
SVB Leerink analyst Andrew Berens maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $50 to $64.
44 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
AgriFORCE Growing Systems, Ltd. (NASDAQ: AGRI) shares climbed 105.3% to $4.4350. AgriFORCE Growing Systems reported binding LOI to acquire a European agriculture/horticulture and agtech consulting firm for $29 million.
Nurix Therapeutics Will Present Initial Target Degradation Data From First Phase 1 Trial Of NX-2127 In B Cell Malignancies At Targeted Protein Degradation Summit Wednesday, Oct. 27, 2021 At 11:45 a.m. EDT, Will Host Call At 8:30 a.m.
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that the Company will present initial pharmacokinetic and pharmacodynamic data
Nurix Therapeutics Q3 EPS $(0.65) Down From $(0.59) YoY, Sales $10.25M Up From $4.08M YoY
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.65) per share. This is a 10.17 percent decrease over losses of $(0.59) per share from the same period last year. The company reported $10.25 million in
SVB Leerink Initiates Coverage On Nurix Therapeutics with Outperform Rating, Announces Price Target of $50
SVB Leerink analyst Andrew Berens initiates coverage on Nurix Therapeutics (NASDAQ:NRIX) with a Outperform rating and announces Price Target of $50.
Return on Capital Employed Insights for Nurix Therapeutics
After pulling data from Benzinga Pro it seems like during Q2, Nurix Therapeutics (NASDAQ:NRIX) brought in sales totaling $7.09 million. However, earnings decreased 7.72%, resulting in a loss of $26.41 million.